Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 11:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 455 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Crystalloid administration Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Saline Versus Lactated Ringer's Solution: The SOLAR Fluid Trial

NCT02565420
View directory record Official record
Conditions
Postoperative Complications
Interventions
Normal saline, Lactated Ringer's solution
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
8,616 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 10, 2019 · Synced Sep 2, 2026, 11:19 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes

NCT00787176
View directory record Official record
Conditions
Pregnancy, Labor Pain
Interventions
Group A Intravenous bolus of 1000 ml lactated ringers solution, Group B Intravenous bolus bolus 1000 ml lactated ringers solution oxytocin decrease to 1/2 current rate, Group C 125 mL/hr of lactated ringers, Group D 125 mL/hr lactated ringers oxytocin decreased to 1/2 current rate
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Sep 2, 2026, 11:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

IV Glucose for Dehydration Treatment

NCT01285713
View directory record Official record
Conditions
Dehydration
Interventions
5% Dextrose (D5) in Normal Saline (NS), Normal Saline (NS)
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Months to 12 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 2, 2026, 11:19 PM EDT
Completed Phase 2 Interventional Results available

Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease

NCT00934362
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lucinactant first, Placebo first
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
14 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 2, 2026, 11:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon

NCT05935527
View directory record Official record
Conditions
Lower Eyelid Steatoblepharon
Interventions
POLAT-001, Placebo
Drug
Lead sponsor
Peregrine Ophthalmic
Industry
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Newport Beach, California • Coral Gables, Florida • Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 2, 2026, 11:19 PM EDT
Terminated Phase 4 Interventional Results available

Multi-dose Acetaminophen for Patients Undergoing General Anesthesia

NCT02832687
View directory record Official record
Conditions
Recovery Following Cholecystectomy
Interventions
Acetaminophen, normal saline
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Newark, New Jersey • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 2, 2026, 11:19 PM EDT
Completed No phase listed Observational

International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project

NCT05387811
View directory record Official record
Conditions
Liver Cirrhosis, Acute Kidney Injury, Hepatorenal Syndrome
Interventions
Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy
Combination Product
Lead sponsor
Azienda Ospedaliera di Padova
Other
Eligibility
18 Years and older
Enrollment
1,456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 2, 2026, 11:19 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

NCT01767519
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
BOTOX®, solifenacin, Botox placebo (normal saline), solifenacin placebo
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 2, 2026, 11:19 PM EDT
Terminated Phase 2 Interventional Results available

Safety Study of Nicardipine to Treat Cerebral Vasospasm

NCT01810302
View directory record Official record
Conditions
Cerebral Vasospasm
Interventions
Nicardipine hydrochloride, Preservative-free normal saline
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Sep 2, 2026, 11:19 PM EDT
Completed Phase 2 Interventional Results available

BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Syndrome

NCT02070302
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Benjamin Sucher
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Sep 2, 2026, 11:19 PM EDT
Completed Phase 2 Interventional

Investigation of Sleep in the Intensive Care Unit

NCT03355053
View directory record Official record
Conditions
Delirium, Sleep
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 2, 2026, 11:19 PM EDT
Completed Phase 2 Interventional Results available

BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis

NCT02230956
View directory record Official record
Conditions
Osteoarthritis
Interventions
onabotulinumtoxinA, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 2, 2026, 11:19 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Autologous Platelet-Rich Plasma for Erectile Dysfunction.

NCT04396795
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Autologous Platelet Rich Plasma, Saline solution
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
30 Years to 75 Years · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Sep 2, 2026, 11:19 PM EDT
Recruiting Phase 3 Interventional

Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm

NCT06281977
View directory record Official record
Conditions
Ventricular Tachycardia, Ventricular Arrhythmias, Ventricular Fibrillation, Recurrent Ventricular Tachycardia
Interventions
Dexmedetomidine, Normal saline
Drug
Lead sponsor
Ottawa Heart Institute Research Corporation
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 2, 2026, 11:19 PM EDT
Not listed Phase 1Phase 2 Interventional

Siltuximab in Schizophrenia

NCT02796859
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Siltuximab, normal saline
Drug
Lead sponsor
Brian Miller
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Sep 2, 2026, 11:19 PM EDT
Recruiting Phase 4 Interventional

Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators

NCT07133880
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ), Placebo DPI
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 2, 2026, 11:19 PM EDT
Completed Phase 2 Interventional Results available

N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients

NCT00780962
View directory record Official record
Conditions
Radiocontrast Nephropathy
Interventions
N-Acetylcysteine (NAC), 0.9% Sodium-chloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 2, 2026, 11:19 PM EDT
Terminated Not applicable Interventional

Single Blinded First CMC Osteoarthritis Treatment

NCT03196310
View directory record Official record
Conditions
Osteoarthritis Thumb
Interventions
Platelet Concentrate, Corticosteroid injection, Normal Saline
Drug · Other
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Centerville, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 2, 2026, 11:19 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

NCT01381926
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Bone Remodeling
Interventions
exenatide, Saline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
45 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 2, 2026, 11:19 PM EDT
Recruiting Phase 4 Interventional

Regional Anesthesia in Minimally Invasive Lumbar Spine Surgery

NCT05029726
View directory record Official record
Conditions
Lumbar Spinal Stenosis, Lumbar Disc Herniation, Lumbar Spondylolisthesis, Lumbar Spondylosis, Lumbar Radiculopathy, Lumbar Spine Instability, Synovial Cyst, Degenerative Disc Disease, Degenerative Spondylolisthesis, Degenerative Intervertebral Discs
Interventions
Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine, normal saline
Drug
Lead sponsor
John O'Toole
Other
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 2, 2026, 11:19 PM EDT
Terminated Phase 2 Interventional

Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy

NCT00742612
View directory record Official record
Conditions
Intracranial Embolism, Cerebral Thromboembolism, Carotid Stenosis
Interventions
ARC1779 Injection, Placebo (normal saline)
Drug
Lead sponsor
Archemix Corp.
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Hackensack, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2010 · Synced Sep 2, 2026, 11:19 PM EDT
Terminated Phase 3 Interventional Results available

VA CoronavirUs Research and Efficacy Studies-1

NCT04539275
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent Plasma, Masked Saline Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Sep 2, 2026, 11:19 PM EDT
Completed Phase 4 Interventional Results available

Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)

NCT01833130
View directory record Official record
Conditions
Chronic Migraine
Interventions
OnabotulinumtoxinA, Normal saline (placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Sep 2, 2026, 11:19 PM EDT
Completed Phase 2 Interventional Results available

Mannitol - Potential Role in Hemodialysis Initiation for Reduction of Intra-dialytic Hypotension

NCT01520207
View directory record Official record
Conditions
Intra-dialytic Hypotension
Interventions
Mannitol (20%), 0.9% saline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 2, 2026, 11:19 PM EDT